Study of JS207 with or without JS015 and chemo for colorectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination (JS207 with or without JS015) along with chemotherapy for people with advanced colorectal cancer that has not spread to other parts of the body. It aims to see if the treatment is safe and helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage 4 colorectal cancer that is MSS or pMMR type (a lab test will confirm this).
- You have not had any chemotherapy or other systemic treatment for advanced cancer before, though prior treatment before surgery is okay if it's been over 12 months.
- You are in generally good health, able to care for yourself, and have at least one tumor that can be measured on scans.
- You have no active infections, heart problems, or major bleeding risks.
- You agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, MRG007, combined with other treatments for advanced colorectal cancer. The goal is to see if this combination can shrink tumors or slow the cancer's growth when standard treatments have not worked.
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called JSKN027 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this drug is safe and if it can shrink tumors or slow their growth.
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
Hear when a new Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.